Birger Sørensen
Chairman
- Cand.real /MSc, Physical Chemistry (minors: Mathematics and Biochemistry), University of Tromsø.
- Founder President and CEO of original Bionor Immuno AS (2000).
- Chairman of the Norwegian Bio Industry Association (2006 -2010).
- EVP and Head of Vaccines Bionor Pharma ASA, Directed vaccine R&D – 31 peer-reviewed publications and a range of patents covering Vacc-4x, Vacc-C5, COVID vaccines and others.
Aslak Aslaksen
Board Member
- Aslak Aslaksen holds Master of Law degrees from the University of Oslo and Harvard Law School.
- Extensive experience as partner in law firms.
- Investor and project developer in Renewable Energy, Biotech, Mining & Minerals.
- Member of Oslo City Council 2007 – 2015.
Dag Arne Wivelstad
Board Member
- Siv.ok, BI, Oslo and MBA Finance, University of Wisconsin, Madison – USA
- Former Alfred Berg, ABG Sundal Collier and SEB Enskilda
- Investor and project developer
Cecilia Söderberg-Nauclér
Advisor to the BOD
- Medical Doctor, Neurologkliniken, Karolinska Universitetssjukhuset.
- Professor in Medical Mikrobial Patogenesis, Karolinska Institutet, Stockholm, Sweden.
- Professor in Immunology, Turku University, Turku, Finland.
- Virology, immunology and pathogenesis research 30+ years.
Gwythian Prins
Advisor to the BOD
- Research Professor Emeritus of the London School of Economics
- Wide-ranging experience in business, government, medicine, and academia. By original discipline an historian and anthropologist who worked on the social epidemiology of TB in Africa, he previously taught at Cambridge University and was a Fellow of Emmanuel College. After joining the Immunor team in 2019, he assisted with forensic historical research into the genetic lineage of the target virus SARS-CoV-2. Professor Prins has been a shadow author involved in all the COVID and vaccine papers published by the Immunor team.
Per Bengtsson
Advisor to the BOD
- MD PhD Karolinska Institutet
- Former CMO Bionor Immuno AS, former CEO Karobio, Sweden.
Senior Management
Andres Schjønhaug Susrud
CEO/CTO
- MSc, Statistics – Modelling & data analysis (minors: Financial mathematics, insurance mathematics & risk), University of Oslo.
- Co-founder of Immunor AS (2014)
- Actuarial consultant 2012-2017 (Deloitte 2013-2017)
- Financial Controller W.R Berkley Insurance Europe Nordic (2017-2020)
Peder Bjørge Kristiansen
COO/CFO
- MSc. in Business and Economics (Norwegian Business School, BI)
- Senior Advisor Corporate Finance and M&A (Weibull 2018-2023)
- CEO/CFO, Management Consultant and Project Manager in the media tech industry (2011-2018)
- Senior Advisor Compliance Risk (The Norwegian Tax Authority 2010-2011)
- Business Consultant (Sopra Steria 2008-2010)
Angus Dalgleish
Chief Scientific Officer
- One of the UK’s leading research immunologists, as well as a leading clinician.
- Foundation Professor of Oncology at St Georges, University of London and also the Principal of the Institute for Cancer Vaccines and Immunology.
- A ‘disruptive’ thinker, he is the author of over 400 scientific papers, pioneered the concept of cancer vaccines and immunotherapy in the UK. He made formative discoveries in the progression of HIV to AIDS which underpin the triple therapy protocol and will make possible the prevention and cure package that is Immunor’s lead product and ‘proof of concept’ of the CPSPVP platform.